OpenAI ends its API partnership with Cursor after SpaceX's $60B acquisition of the coding startup

OpenAI announced via an official blog post last Friday that it is winding down its API partnership with Cursor, the AI coding editor SpaceX acquired for a reported $60 billion. OpenAI's stated reason is that it cannot trust SpaceX to abide by its terms of service. Cursor was reportedly a top-five OpenAI customer, with OpenAI estimating in spring 2026 that it generated over $1 billion in annualized revenue. The exact wind-down timeline, contract terms and what alternative model access Cursor retains (its own models, Anthropic's Claude, etc.) are not detailed in the reporting.

Cursor developers lose direct API access to OpenAI models (GPT-5, Codex) inside a widely used coding tool, likely pushing them toward Claude or Cursor's own models, which benefits Anthropic and other competitors in the near term. It signals OpenAI is willing to forgo significant, verifiable revenue to avoid commercial ties to Musk, who is both a litigant against OpenAI and running a competing lab (xAI). This is a concrete data point on how personal and legal conflicts between AI labs are now reshaping commercial contracts, not just rhetoric.

The "$1 billion in annualized revenue" figure is OpenAI's own spring 2026 estimate, not an audited or independently verified number, and should be treated as directional rather than precise. The framing that this move is primarily about making OpenAI "IPO-ready" is interpretive commentary, not something OpenAI has confirmed as its motive. A disputed traffic-share claim referenced in the underlying reporting is unverified and should be disregarded until sourced.

1. 01Whether OpenAI or Cursor publish specific wind-down dates or a transition period for existing API access
2. 02Cursor's public statements on which models (Anthropic, its own, or others) will replace OpenAI access, and any pricing or capability changes for users
3. 03Whether other OpenAI enterprise customers with Musk-linked ownership or investment ties face similar contract reviews in the coming months